Drugbox
IUPAC_name = (1"S",3a"R",6a"S")-2- [(2"S")-2- [(2"S")-2-Cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl] amino] -3,3-dimethylbutanoyl] -"N"- [(3"S")-1-(cyclopropylamino)-1,2-dioxohexan-3-yl] -3,3a,4,5,6,6a-hexahydro-1"H"-cyclopenta [c] pyrrole-1-carboxamide
CAS_number = 402957-28-2
ATC_prefix =
ATC_suffix =
PubChem = 3010818
DrugBank =
C=36|H=53|N=7|O=6
molecular_weight = 679.85 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =
Telaprevir, also known as VX-950, co-developed by Vertex and Johnson & Johnson, is an experimental treatment for hepatitis C that has successfully completed phase I[cite journal | author=Reesink HW, Zeuzem S, Weegink CJ, "et al." | title=Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study | journal=Gastroenterology | year=2006 | volume=131 | pages=997–1002 | doi=10.1053/j.gastro.2006.07.013 ] and phase II clinical trials. [ [http://www.hivandhepatitis.com/2008icr/easl/docs/042508_b.html Telaprevir plus Pegylated Interferon and Ribavirin Allows Shorter Therapy for Patients with Genotype 1 HCV ] ] It is a member of a class of antiviral drugs known as protease inhibitors. [cite journal | journal = Drugs of the Future | year = 2007 | volume = 32 | issue = 9 | pages = 788 | title = Telaprevir | author = Revill, P., Serradell, N., Bolos, J., Rosa, E. | url = http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryt_pr?p_type=1959f8821565c34e42a0f67c3fe47e&p_JournalId=2&p_RefId=1138229] Phase III trials are ongoing. [ [http://www.hivandhepatitis.com/hep_c/news/2008/020108_a.html Vertex to Start Phase 3 Trials of HCV Protease Inhibitor Telaprevir (VX-950)] ] [ [http://www.fiercebiotech.com/story/vertex-readies-new-phase-iii-trial-telaprevir/2008-08-19 Vertex readies new Phase 3 trial of telaprevir] , Aug 19, 2008.] ]Telaprevir is the first hepatitis drug currently in development that has demonstrated activity in patients who have failed prior therapy. [cite journal| journal = Nature Reviews Drug Discovery | volume = 7 | pages = 799-800 | year = 2008 | title = Hepatitis C therapies | author = Irena Melnikova | doi = 10.1038/nrd2661]
References
